To assess the clinical effects and safety of Huangqi Jianzhong Tang HQJZ for the treatment of chronic gastritis CG, three English databases and four Chinese databases were searched through the inception to January 2015. In randomized controlled trials RCTs comparing HQJZ with placebo, no intervention and western medicine were included. A total of 9 RCTs involving 979 participants were identified. The methodological quality of the included trials was generally poor. Meta-analyses demonstrated that HQJZ plus conventional medicine was more effective in improving overall gastroscopy outcome than western medicine alone for treatment of chronic superficial gastritis with the pooling result of overall improvement OR 3.78 , . In addition, the combination of HQJZ with antibiotics has higher overall effect rate than antibiotics alone for the treatment of CG OR 2.60 , . There were no serious adverse events reported in both the intervention and controlled groups. HQJZ has the potential of improvement of the patients’ gastroscopy outcomes, Helicobacter pylori clearance rate, traditional Chinese Medicine syndromes, and overall effect rate alone or in combination use with conventional western medicine for chronic atrophic gastritis. However, due to poor methodological quality, the beneficial effect and safeties of HQJZ for CG could not be confirmed.